Effect of Coexisting Advanced Extrapulmonary Solid Cancer on Progression of Mycobacterium Avium Complex Lung Disease

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2021 May 19

PMID 34008760

Citations 2

Authors

Rei Inoue

Keisuke Watanabe

Yusuke Saigusa

Nobuyuki Hirama

Yu Hara

Nobuaki Kobayashi

Makoto Kudo

Takeshi Kaneko

Affiliations

Soon will be listed here.

Abstract

Objective: Although Mycobacterium avium complex (MAC) lung disease has been shown to be associated with lung cancer and hematologic malignancies, there have been few studies of its relationships with other types of cancer. The aim of this study was to assess the effect that coexisting advanced extrapulmonary solid tumors have on the progression of MAC lung disease.

Methods: This was a retrospective study of patients diagnosed with MAC lung disease, on the basis of the American Thoracic Society (ATS) criteria, between October of 2005 and March of 2019. The patients were divided into three groups: those with advanced-stage cancer (A-SC group); those with early-stage cancer (E-SC group); and those without cancer (control group). Progression of MAC lung disease was defined as exacerbation seen on imaging. Patient characteristics and the time to progression were compared among the three groups.

Results: A total of 286 patients met the ATS diagnostic criteria for MAC lung disease, and 128 of those were excluded. Of the remaining 158 patients, 20 (7.0%) were in the A-SC group, 36 (12.6%) were in the E-SC group, and 102 (35.7%) were in the control group. The median time to progression in the A-SC, E-SC, and control groups was 432, 3,595, and 2,829 days, respectively (p < 0.01). A proportional hazards model showed that the significant predictors of MAC lung disease progression were advanced-stage cancer (hazard ratio [HR] = 6.096; 95% CI: 2.688-13.826; p < 0.01), cavitary lesions (HR = 2.750; 95% CI: 1.306-5.791; p < 0.01), and a high Nodule-Infiltration-Cavity-Ectasis score (HR = 1.046; 95% CI: 1.004-1.091; p = 0.033).

Conclusions: A coexisting advanced extrapulmonary solid tumor could hasten the progression of MAC lung disease.

Citing Articles

Combination of anti-glycopeptidolipid-core IgA antibody and clinical features for diagnosing potential nontuberculous mycobacterium pulmonary disease in routine practice.

Iwasaki T, Yamaguchi F, Hayashi M, Kobayashi H, Hirata K, Miyo K Ther Adv Respir Dis. 2022; 16:17534666221138002.

PMID: 36444981 PMC: 9716443. DOI: 10.1177/17534666221138002.

Tuberculosis Series 2021.

Silva D, Mello F, Migliori G J Bras Pneumol. 2021; 47(2):e20210109.

PMID: 33950097 PMC: 8332828. DOI: 10.36416/1806-3756/e20210109.

References

Pan S, Shu C, Feng J, Wang J, Chan Y, Yu C . Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression. Clin Infect Dis. 2017; 65(6):927-934. DOI: 10.1093/cid/cix479. View

Lin C, Russell C, Soll B, Chow D, Bamrah S, Brostrom R . Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Jurisdictions. Emerg Infect Dis. 2018; 24(3):485-491. PMC: 5823340. DOI: 10.3201/eid2403.171301. View

Diel R, Lipman M, Hoefsloot W . High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018; 18(1):206. PMC: 5934808. DOI: 10.1186/s12879-018-3113-x. View

Kawabata-Shoda E, Charvat H, Ikeda A, Inoue M, Sawada N, Iwasaki M . Trends in cancer prognosis in a population-based cohort survey: can recent advances in cancer therapy affect the prognosis?. Cancer Epidemiol. 2014; 39(1):97-103. DOI: 10.1016/j.canep.2014.11.008. View

Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View

Chen C, Sheng W, Lai C, Liao C, Huang Y, Tsay W . Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis. 2011; 31(6):1059-66. DOI: 10.1007/s10096-011-1407-7. View

Noguchi S, Yatera K, Yamasaki K, Kawanami T, Takahashi T, Shimabukuro I . A Case of Rapid Exacerbation of Pulmonary Mycobacterium Avium Complex Infection Mimicking Pulmonary Aspergillosis. J UOEH. 2015; 37(3):177-83. DOI: 10.7888/juoeh.37.177. View

Lai C, Tan C, Chou C, Hsu H, Liao C, Huang Y . Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis. 2010; 16(2):294-6. PMC: 2958002. DOI: 10.3201/eid1602.090675. View

Thomson R . Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010; 16(10):1576-83. PMC: 3294381. DOI: 10.3201/eid1610.091201. View

10.

Macacu A, Autier P, Boniol M, Boyle P . Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015; 154(2):213-24. DOI: 10.1007/s10549-015-3628-4. View

11.

Vucicevic Boras V, Fucic A, Baranovic S, Blivajs I, Milenovic M, Bisof V . Environmental and behavioural head and neck cancer risk factors. Cent Eur J Public Health. 2019; 27(2):106-109. DOI: 10.21101/cejph.a5565. View

12.

Tamura A, Hebisawa A, Kusaka K, Hirose T, Suzuki J, Yamane A . Relationship Between Lung Cancer and Mycobacterium Avium Complex Isolated Using Bronchoscopy. Open Respir Med J. 2016; 10:20-8. PMC: 4892172. DOI: 10.2174/1874306401610010020. View

13.

Meier E, Pennington K, de Moraes A, Escalante P . Characteristics of (MAC) pulmonary disease in previously treated lung cancer patients. Respir Med Case Rep. 2017; 22:70-73. PMC: 5491758. DOI: 10.1016/j.rmcr.2017.06.012. View

14.

Gondos A, Bray F, Hakulinen T, Brenner H . Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2008; 20(3):564-73. DOI: 10.1093/annonc/mdn639. View

15.

Kim H, Hwang S, Ro Y, Jeon C, Ha D, Park S . Solid-organ malignancy as a risk factor for tuberculosis. Respirology. 2008; 13(3):413-9. DOI: 10.1111/j.1440-1843.2008.01282.x. View

16.

Kim S, Park J, Lee H, Lee Y, Park J, Cho Y . Risk factors for deterioration of nodular bronchiectatic Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2014; 18(6):730-6. DOI: 10.5588/ijtld.13.0792. View

17.

Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y . Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015; 5(8):e008058. PMC: 4538251. DOI: 10.1136/bmjopen-2015-008058. View

18.

Lai C, Tan C, Cheng A, Chung K, Chen C, Liao C . Nontuberculous mycobacterial infections in cancer patients in a medical center in Taiwan, 2005-2008. Diagn Microbiol Infect Dis. 2011; 72(2):161-5. DOI: 10.1016/j.diagmicrobio.2011.10.006. View

19.

. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis. 2002; 6(7):628-34. View

20.

Prevots D, Shaw P, Strickland D, Jackson L, Raebel M, Blosky M . Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010; 182(7):970-6. PMC: 2970866. DOI: 10.1164/rccm.201002-0310OC. View